NCT05997524View on ClinicalTrials.gov

Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

June 30, 2023

Conditions
Advanced Gastric Carcinoma
Interventions
DRUG

Trastuzumab

Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).

DRUG

Oxaliplatin

Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.

DRUG

Capecitabine

Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.

Trial Locations (1)

1000

Bangabandhu Sheikh Mujib Medical University, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

NCT05997524 - Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. | Biotech Hunter | Biotech Hunter